



Unlock. Your. Resilience.


Ingredient Overview

Patented | GRAS | Vegetarian | Allergen-free | Non-GMO | Heat-stable

IMMUSE[™]
(LC-Plasma)


IMMUSE™ Science Snapshot

What are Postbiotics?



Postbiotics like IMMUSE™ (*Lactococcus lactis* JCM 5805) are defined as dead bacteria or dead probiotics with health benefits.*

What are Plasmacytoid Dendritic Cells (pDC)?



pDCs are a rare subset of immune cells that have been described as a key leader of the immune system.*

IMMUSE™: Novel Immune Support

25+ Studies
11 Human Trials


Researched by Kirin and backed by more than 25 studies, including 11 human trials, IMMUSE is the first postbiotic to directly activate plasmacytoid dendritic cells, consequentially providing more comprehensive immune support.*

Key IMMUSE™ Studies

IMMUSE activates pDC*¹

Researchers studied the effects of IMMUSE and its ability to increase pDC activation markers in fifty-one healthy subjects in a gold-standard trial.

■ IMMUSE™ ■ PLACEBO




IMMUSE significantly increased CD86, a key activation marker of pDC, in the group who ingested IMMUSE.*

IMMUSE supports respiratory health*²

Researchers carried out a randomized, double-blind study on 213 healthy subjects during the winter season.

■ Severe ■ Moderate ■ Mild ■ Slight




Measured over a 10-week period, individuals who consumed yogurts formulated with IMMUSE, increased respiratory health.*

Supports exercise performance by activating immune system*¹

Researchers carried out a randomized, double-blind study on fifty-one male athletes part of a university sports club. (Accumulated subjective symptoms of physical condition and fatigue after exercise.)

† Statistically significant (p < 0.05)



Individuals who consumed IMMUSE increased their respiratory health, followed by reduced fatigue level.*

Unlock the key to comprehensive immune support with IMMUSE™*

1. Komano Y, et al., Efficacy of heat-killed *Lactococcus lactis* JCM 5805 on immunity and fatigue during consecutive high intensity exercise in male athletes: A randomized, placebo-controlled, double-blinded trial. *J Int Soc Sports Nutr.* 2018;15(1):39.
2. Sugimura T, et al., Effects of oral intake of plasmacytoid dendritic cells-stimulative lactic acid bacterial strain on pathogenesis of influenza-like illness and immunological response to influenza virus. *British Journal of Nutrition.* 2015;114(5):727-733.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

IMMUSE™ Scientific Advantages

Over the last several years **immune support** has become one of the top three reasons why consumers purchase supplements. Furthermore, according to a recent consumer survey, 60% of consumers worldwide are conscious about their immunity. *Nutrition Business Journal* predicts the immune health supplements market to reach \$6.0B in supplement sales in 2021. With increase in demand, consumers are looking to innovative ingredients and functional foods and beverages to keep their immune system in balance.

60% of consumers worldwide
Are conscious about their immunity

\$6.0 Billion
Immune Health Dietary Supplement Market

69.9% Growth

IMMUSE™, a novel postbiotic strain, *Lactococcus lactis* strain Plasma (LC-Plasma), discovered by KIRIN has been shown to:

1. Provide clinically researched immune support*
2. Activate the immune system via pDC (plasmacytoid dendritic cells)*
3. Proactively support the immune system*
4. Stimulate body's natural defenses*

What is IMMUSE™?

IMMUSE LC-Plasma is the first lactic acid bacteria that has been clinically researched to directly activate pDCs, a rare subset of immune cells, to provide comprehensive innate and adaptive immune support.* IMMUSE is supported by more than 25 studies including 11 human clinical trials. IMMUSE is also self-affirmed GRAS and applicable to wide variety of applications including tablets, capsules and foods.



What are Postbiotics?

Postbiotics are inactivated (non-viable) probiotics with health benefits similar to those by live probiotics. Postbiotics also provide the added advantage that they have a longer shelf-life and play a vital role in improving immune health by supporting immune-modulation benefits.* IMMUSE, a patented postbiotic, is a heat-killed *Lactococcus lactis* strain Plasma that has been shown to provide immune support at a cellular level.*

Bridging the Gap

The immune system is a complex structure that resides throughout our body. It contains many immune cell types, such as NK cells, T cells, B cells, Dendritic cells, Macrophages, and others that keeps your immune system functioning. Many of these cells are divided into two areas, innate and adaptive. The innate immune system provides the body, the first-line of defense against foreign substances. The adaptive immune system is more specialized and creates "muscle memory" to make the immune system quicker and more resilient the next time it comes in contact with a pathogen.

Unlike most of the immune cells, pDCs straddle between innate and adaptive immune systems, playing a pivotal role within the immune system.* pDC have been described as key leaders of the immune system since they activate essential immune cells and provide more comprehensive immune support.*

Pioneering Fermentation


Kirin has widely been recognized as a fermentation leader for over 130-years. As part of the Kirin group, Kyowa Hakko Bio is committed to improving lives through health science. In partnership with Kirin and Koivai Dairy, a leading manufacturer of dairy products, we discovered the power of lactic acid bacteria for proactively managing immune health.*

Why IMMUSE?

A strong immune system is critical for good health. Add IMMUSE, a novel postbiotic, to your next immune health formula and get your customer's immune system on the offense.*

- Activates pDC, leader of the immune system*
- Backed by more than 25 studies
- Provides year-round immune support*

We're ready to fulfill your order at our JFS-C certified facility.



To learn more about
IMMUSE,

[WATCH VIDEO >>](#)

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

IMMUSE™ Marketing Advantages



Superior Formulation Benefits

Manufacturers and formulators will love the more practical benefits of IMMUSE™.

- **Postbiotic.** IMMUSE is a postbiotic, which means no need to worry about survivability of bacteria like you have to with probiotics.
- **Heat-stable.** IMMUSE is a heat-treated probiotic that is stable and heat resistant compared to probiotics, which means no refrigeration is needed.
- **Can be formulated in foods.** IMMUSE is self-affirmed GRAS and its efficacy has been proven in various foods over the last 10+ years.
- **Pure.** IMMUSE is a pure heat-stable powder that doesn't contain any food additives, artificial colors, artificial flavors or preservatives.
- **Vegetarian.** No animal origin material is used in IMMUSE.
- **Allergen-free.** IMMUSE doesn't contain any preservatives, artificial flavor or colors, wheat, grains, nuts, eggs, dairy, seafood, and animal derivatives.

- **Cell culture production.** IMMUSE is made using a proprietary cultivation process.
- **Patented.** Kirin owns the global patent (US09549956) on IMMUSE.
- **Non-GMO.**

IMMUSE™ Product Applications

IMMUSE is a unique health ingredient that can be incorporated into a wide range of finished products designed to support immunity, productivity and overall performance:

- Dietary supplements
- Cereals
- Protein bars
- Yogurts

IMMUSE is Backed by Kyowa Hakko

Kyowa Hakko is an international health ingredient manufacturer and a world leader in the development, manufacturing and marketing of nutraceuticals, pharmaceuticals and food products. Part of Kyowa's dedication to ongoing

scientific research, quality management and consumer education, IMMUSE leads the way in immune health research.



Your Immune Advantage

IMMUSE activates pDC (plasmacytoid dendritic cells) which are crucial to stimulating your body's natural defenses.*



Sports Nutrition Support

IMMUSE proactively supports the immune system for exercise.*



Productivity Support

IMMUSE's immune-supporting properties may also promote productivity at work.*

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

IMMUSE™ Scientific References:

1. Jounai K, Ikado K, Sugimura T, Ano Y, Braun J, Fujiwara D. (2012) Spherical lactic acid bacteria activate plasmacytoid dendritic cells immunomodulatory function via TLR9-dependent cross-talk with myeloid dendritic cells. *PLoS One* 7: e32588.
2. Sugimura T, Jounai K, Ohshio K, Tanaka T, Suwa M, Fujiwara D. (2013) Immunomodulatory effect of *Lactococcus lactis* JCM5805 on human plasmacytoid dendritic cells. *Clin Immunol* 149: 509–518.
3. Jounai K, Sugimura T, Ohshio K, Fujiwara D. (2015) Oral administration of *Lactococcus lactis* subsp. *lactis* JCM5805 enhances lung immune response resulting in protection from murine parainfluenza virus infection. *PLoS One*. 6: e0119055.
4. Fujii T, Tomita Y, Ikushima S, Horie A, Fujiwara D. (2015) Draft genome sequence of *Lactococcus lactis* subsp. *lactis* JCM 5805T, a strain that induces plasmacytoid dendritic cell activation. *Genome Announc* 3 : e00113-15
5. Sugimura T, Takahashi H, Jounai K, Ohshio K, Kanayama M, Tazumi K, Tanihata Y, Miura Y, Fujiwara D, Yamamoto N. (2015) Effects of oral intake of plasmacytoid dendritic cells-stimulative lactic acid bacterial strain on pathogenesis of influenza-like illness and immunological response to influenza virus. *Br J Nutr*. 3:1-7.
6. Suzuki H, Kanayama M, Fujii T, Fujiwara D, Sugimura K (2015) Effects of the beverage containing *Lactococcus lactis* subsp. *lactis* JCM5805 on anti-viral immune responses and maintenance of physical conditions -a randomized, double-blind, placebo-controlled, parallel-group Trial— *Jpn Pharmacol Ther*. 43:1465-72.
7. Tanaka K, Suzuki H, Kanayama M, Fujii T, Fujiwara D, Nozawa H, Sugimura K. (2015) The safety evaluation of long-term or excessive intake of the beverage containing *Lactococcus lactis* subsp. *lactis* JCM 5805 and resistant maltodextrin -a randomized, double-blind, placebo-controlled, parallel-group trial— *Jpn Pharmacol Ther*. 43:1711-27.
8. Suzuki H, Ohshio K, Fujiwara D. (2016) *Lactococcus lactis* subsp. *lactis* JCM5805 activates natural killer cells via dendritic cells. *Biosci Biotech Biochem*. 80: 798-800.
9. Shibata T, Kanayama M, Haida M, Fujimoto S, Oroguchi T, Sata K, Mita N, Kutsuzawa T, Ikeuchi M, Kondo M, Naito K, Tsuda M, Nishizaki Y, Ishii N. (2016) *Lactococcus lactis* JCM5805 activates anti-viral immunity and reduces symptoms of common cold and influenza in healthy adults in a randomized controlled trial. *J Func Food*. 24: 492-500.
10. Sakata K, Sasaki Y, Jounai K, Fujii T, Fujiwara D. (2017) Preventive effect of *Lactococcus lactis* subsp. *lactis* JCM 5805 yogurt intake on influenza infection among schoolchildren. *Health* 9: 756-762.
11. Fujii T, Jounai K, Horie A, Takahashi H, Suzuki H, Ohshio K, Fujiwara D, Yamamoto N. (2017) Effects of heat-killed *Lactococcus lactis* subsp. *lactis* JCM 5805 on mucosal and systemic immune parameters, and antiviral reactions to influenza virus in healthy adults; A randomized controlled double-blind study. *J Func Food*. 35: 513-521.
12. Jounai K, Sugimura T, Morita Y, Ohshio K, Fujiwara D. (2018) Administration of *Lactococcus lactis* strain Plasma induces maturation of plasmacytoid dendritic cells and protection from rotavirus infection in suckling mice. *Int Immunopharmacol*, 56: 205-211.
13. Kanayama M, Kato Y, Tsuji T, Konoeda Y, Hashimoto A, Kanauchi O, Fujii T, Fujiwara D. (2018) Enhancement of immunomodulatory effect of lactic acid bacteria on plasmacytoid dendritic cells with sucrose palmitate. *Sci Rep*, 8: 3147.
14. Sugimura T, Jounai K, Ohshio K, Suzuki H, Kirisako T, Sugihara Y, Fujiwara D. (2018) Long-term administration of pDC-stimulative *Lactococcus lactis* strain decelerates senescence and prolongs the lifespan of mice. *Int Immunopharmacol*, 58:166-172.
15. Tsuji R, Komano Y, Ohshio K, Ishii N, Kanauchi O. (2018) Long-term administration of pDC stimulative lactic acid bacteria, *Lactococcus lactis* strain Plasma, prevents immune-senescence and decelerates individual senescence. *Exp Gerontol*, 111: 10-16.
16. Suzuki H, Jounai K, Ohshio K, Fujii T, Fujiwara D. (2018) Administration of plasmacytoid dendritic cell-stimulative lactic acid bacteria enhances antigen-specific immune responses. *Biochem Biophys Res Commun*, 503: 1315-1321.
17. Kato Y, Kanayama M, Yanai S, Nozawa H, Kanauchi O, Suzuki S. (2018) Safety evaluation of excessive intake of *Lactococcus lactis* subsp. *lactis* JCM 5805: A randomized, double-blind, placebo-controlled, parallel-group trial. *Food Nutr Sci*, 9:403-419.
18. Komano Y, Shimada K, Naito H, Fukao K, Ishihara Y, Fujii T, Kokubo T, Daida H. (2018) Efficacy of heat-killed *Lactococcus lactis* JCM 5805 on immunity and fatigue during consecutive high intensity exercise in male athletes: a randomized, placebo-controlled, double-blinded trial. *J Int Soc Sports Nutr*, 15:39.
19. Suzuki H, Tsuji R, Sugamata M, Yamamoto N, Yamamoto N, Kanauchi O. (2019) Administration of plasmacytoid dendritic cell stimulative lactic acid bacteria is effective against dengue virus infection in mice. *Int J Mol Med*, 43:426-434.
20. Tsuji R, Yamamoto N, Yamada S, Fujii T, Yamamoto N, Kanauchi O. (2018) Induction of anti-viral genes mediated by humoral factors upon stimulation with *Lactococcus lactis* strain Plasma results in repression of dengue virus replication in vitro. *Antiviral Res*, 160:101-108.
21. Kokubo T, Komano Y, Tsuji R, Fujiwara D, Fujii T and Kanauchi O. (2019) Plasmacytoid dendritic cell-stimulative lactic acid bacteria, *Lactococcus lactis* strain Plasma, relieves exercise-induced fatigue and aids recovery via immuno-modulatory action. *Int J Sport Nutr Exer Metabol*, 5:1-5, 2019.
22. Horie A, Tomita Y, Ohshio K, Fujiwara D, Fujii T. (2019) Characterization of genomic DNA of lactic acid bacteria for activation of plasmacytoid dendritic cells. *BMC Microbiol*, 19: 88, 2019.
23. Tsuji R, Fujii T, Nakamura Y, Yazawa K, Kanauchi O. (2019) *Staphylococcus aureus* epicutaneous infection is suppressed by *Lactococcus lactis* strain Plasma via IL-17A elicitation. *J Infect Dis*, Jul 31;220(5):892-901 2019.
24. Sugimura T, Jounai K, Ohshio K, Fujiwara D. (2019) Plasmacytoid dendritic cell dysfunction caused by heat stress is improved by administration of *Lactococcus lactis* strain Plasma in mice. *Biosci Biotech Biochem*, Jul 18:1-4. 2019.
25. Takeshi Kokubo, Shimpai Wakai, Daisuke Fujiwara, Osamu Kanauchi, Kenta Jounai, Hisahiro Ichikawa, Mihoko Takuma, Yoshihisa Kanaya, and Ryohei Shiraoka (2020) *Lactococcus-lactis*-Strain-Plasma-Improves-Subjective-Physical-State-and-Preteels m-A-Randomized-Open-Label-Crossover-Study-among-Healthy-Office-Workers *Prev Nutr. Food Sci*. 2020;25(2):140-145
26. Tsuji R, Yazawa K, Kokubo T, Nakamura Y, Kanauchi O. The Effects of Dietary Supplementation of *Lactococcus lactis* Strain Plasma on Skin Microbiome and Skin Conditions in Healthy Subjects—A Randomized, Double-Blind, Placebo-Controlled Trial. *Microorganisms*. 2021; 9(3):563.

IMMUSE™

Generate breakthrough sales with IMMUSE, an ingredient designed to provide more comprehensive immune support.*

For more information on including IMMUSE, visit Kyowa-USA.com or IMMUSEhealth.com.



For more information about IMMUSE contact:

KYOWA HAKKO USA, INC.

Customer Service: 800.596.9252 info@kyowa-usa.com

600 Third Ave. 19th Floor
New York, NY 10016

Tel: 212.319.5353
Fax: 212.421.1283

Kyowa-USA.com
IMMUSEhealth.com



Kirin Co., Ltd owns the global patent (US09549956) on IMMUSE

Copyright © 2021 KYOWA HAKKO U.S.A., INC.

All Rights Reserved.

IMMUSE™ is a clinically researched lactic acid bacteria developed by Kirin Holdings Co., Ltd.